Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

BioPharma Terug naar discussie overzicht

Heeft CytoDyn het ultieme anti-HIV-middel??

1.071 Posts
Pagina: «« 1 ... 34 35 36 37 38 ... 54 »» | Laatste | Omlaag ↓
  1. [verwijderd] 12 augustus 2020 21:55
    Dit is echt belangrijk voor CytoDyn. Fauci uit de buurt...

    fc

    Dr. Scott Atlas, the anti-Fauci Stanford doctor, joins the White House Coronavirus Task Force team

    Back in June, we wrote about Dr. Scott Atlas when the former chief of neuroradiology at Stanford University Medical Center and a senior fellow at Stanford’s Hoover Institution, said that the rise in coronavirus hospitalizations among young people is a good thing because it leads to herd immunity over the long term.

    Dr. Atlas, along with the handful of other European doctors, is one of the medical experts telling who thinks herd immunity is one of the best ways to overcome the deadly coronavirus. Unlike Dr, Anthony Fauci, Dr. Atlas told Americans back in June not to panic about the rise in coronavirus cases. Dr. Atlas later got the attention of US President Trump.

    Yesterday, President Trump announced that Dr. Scott Atlas is now joining the Coronavirus Task Force team. President Trump said:

    “…This is Scott Atlas. Do you know that? Right? …Scott is a very famous man who’s also very highly respected — Stanford. And he’s working with us and will be working with us on the coronavirus. And he has many great ideas. And he thinks what we’ve done is really good, and now we’ll take it to a new level. And so it’s great to have Scott working along with us. And we appreciate it very much, Scott. Thank you very much, Scott. Thank you very much.”


    Back in June, Dr Atlas appeared with the host of “The Story with Martha MacCallum.” During the the show, Dr. Atlas said that since everyone who gets hospitalized for any reason is getting tested for COVID-19, the people making up the inflated statistics could actually be “hospitalized for something else” but “classified as COVID-19 hospitalizations.” Dr. Atlas also used the interview to lash out at medical journals. “Medical journals like Lancet are publishing garbage studies on coronavirus,” Dr. Atlas says.

    Also in an op-ed piece in The Hill titled, “The data is in - stop the panic and end the total isolation,” Dr. Atlas provided five facts key facts that are being ignored by those calling for continuing the near-total lockdown:

    Fact 1: The overwhelming majority of people do not have any significant risk of dying from COVID-19.
    Fact 2: Protecting older, at-risk people eliminates hospital overcrowding.
    Fact 3: Vital herd immunity is actually PREVENTED by total isolation policies, prolonging the problem.
    Fact 4: People are dying from being denied other medical care due to hypothetical COVID-19 fatality projections that turned out to be garbage.
    Fact 5: We have a clearly defined population at risk who can be protected with targeted measures.

    techstartups.com/2020/08/11/dr-scott-...
  2. evr68@hotmail.com 13 augustus 2020 10:56
    quote:

    FatCool schreef op 12 augustus 2020 21:55:

    Dit is echt belangrijk voor CytoDyn. Fauci uit de buurt...

    fc

    Dr. Scott Atlas, the anti-Fauci Stanford doctor, joins the White House Coronavirus Task Force team

    Back in June, we wrote about Dr. Scott Atlas when the former chief of neuroradiology at Stanford University Medical Center and a senior fellow at Stanford’s Hoover Institution, said that the rise in coronavirus hospitalizations among young people is a good thing because it leads to herd immunity over the long term.

    Dr. Atlas, along with the handful of other European doctors, is one of the medical experts telling who thinks herd immunity is one of the best ways to overcome the deadly coronavirus. Unlike Dr, Anthony Fauci, Dr. Atlas told Americans back in June not to panic about the rise in coronavirus cases. Dr. Atlas later got the attention of US President Trump.

    Yesterday, President Trump announced that Dr. Scott Atlas is now joining the Coronavirus Task Force team. President Trump said:

    “…This is Scott Atlas. Do you know that? Right? …Scott is a very famous man who’s also very highly respected — Stanford. And he’s working with us and will be working with us on the coronavirus. And he has many great ideas. And he thinks what we’ve done is really good, and now we’ll take it to a new level. And so it’s great to have Scott working along with us. And we appreciate it very much, Scott. Thank you very much, Scott. Thank you very much.”


    Back in June, Dr Atlas appeared with the host of “The Story with Martha MacCallum.” During the the show, Dr. Atlas said that since everyone who gets hospitalized for any reason is getting tested for COVID-19, the people making up the inflated statistics could actually be “hospitalized for something else” but “classified as COVID-19 hospitalizations.” Dr. Atlas also used the interview to lash out at medical journals. “Medical journals like Lancet are publishing garbage studies on coronavirus,” Dr. Atlas says.

    Also in an op-ed piece in The Hill titled, “The data is in - stop the panic and end the total isolation,” Dr. Atlas provided five facts key facts that are being ignored by those calling for continuing the near-total lockdown:

    Fact 1: The overwhelming majority of people do not have any significant risk of dying from COVID-19.
    Fact 2: Protecting older, at-risk people eliminates hospital overcrowding.
    Fact 3: Vital herd immunity is actually PREVENTED by total isolation policies, prolonging the problem.
    Fact 4: People are dying from being denied other medical care due to hypothetical COVID-19 fatality projections that turned out to be garbage.
    Fact 5: We have a clearly defined population at risk who can be protected with targeted measures.

    techstartups.com/2020/08/11/dr-scott-...
  3. forum rang 5 MisterBlues 17 augustus 2020 10:47
    quote:

    lute11 schreef op 13 augustus 2020 22:44:

    Koers blijft maar dalen, een hoop bla bla, maar de echte resultaten laten nu wel erg lang op zich wachten.
    Tot de uitslag S&C kan de koers nog verder dalen. Het sentiment is wat negatiever geworden.

    Het zegt verder niet zo veel.
  4. forum rang 5 MisterBlues 17 augustus 2020 10:49
    Interessante post over het in twijfel trekken van de integriteit van de FDA

    Just a reminder to everyone fearing corruption within the FDA preventing approval:

    -FDA granted Cytodyn the ability to forego a Phase 1 for both trials.
    -FDA granted eIND usage to Cytodyn back in March to treat covid patients.
    -FDA allowed Cytodyn to use the eIND as a phase 2 for severe/critical patients so they could immediately move to phase 3.
    -According to Nader, FDA requested Cytodyn stop with the eIND so they could FOCUS ON THE TRIALS.

    The FDA has been very accommodating to Cytodyn. Nader has said as much multiple times. If they wanted to stop leronlimab from coming to market to treat covid, they would have started doing it months ago.
  5. forum rang 5 MisterBlues 17 augustus 2020 10:51
    FDA bereidt zich erop voor om slagvaardiger te kunnen opereren met de handen zijnde vaccins en virusremmers - zo lijkt het.

    Dr. L from Aug. 12th shareholder call.
    Very last thing he said, "I think we have our 1st drug that works in COVID-19 "
    NP said Cytodyn is taking Leronlimab M/M Ph2 Trial Study TopLine results and requesting EUA from FDA. This is good enough for EUA based on FDA's own mandate in CTAP. FDA's Coronavirus Treatment Acceleration Program from March 2020...Announcement of can be found on link below. See for yourself.

    www.fda.gov/news-events/press-announc...

    Today, the U.S. Food and Drug Administration took important actions to help accelerate the development of prevention and treatment options for COVID-19 by providing new guidance with recommendations for innovators and researchers conducting work in this area. These guidance documents aim to make the process for submitting applications to initiate studies for new drugs and biological products more efficient and outline recommendations for ways to design clinical trials to evaluate safety and effectiveness of these medical products for COVID-19.

    “Our staff continues to work around the clock with the world’s best innovators and researchers to help expedite the development of prevention and treatment options for COVID-19,” said FDA Commissioner Stephen M. Hahn, M.D. “Accelerating the investigation of safe and effective therapies that could benefit people affected by the COVID-19 pandemic is one of the FDA’s highest priorities. We are committed to maximizing our regulatory flexibility and using every tool at our disposal to speed the development and availability of these medical products and believe these new guidances will help innovators and researchers do just that.”

    Quickly after the emergence of this virus, the FDA began working directly with federal health partners, academia and industry to advance medical countermeasures against COVID-19. Given the urgent nature of the pandemic, the FDA launched a new program called the Coronavirus Treatment Acceleration Program to help move new medical products to patients as soon as possible, while at the same time determine whether they are effective and if the benefits outweigh the risks.
    Very last thing he said.
  6. [verwijderd] 17 augustus 2020 11:46
    quote:

    MisterBlues schreef op 17 augustus 2020 10:47:

    [...]

    Tot de uitslag S&C kan de koers nog verder dalen. Het sentiment is wat negatiever geworden.

    Het zegt verder niet zo veel.
    Wanner krijgen we die uitslag?
  7. Dappie 17 augustus 2020 14:26
    2 nieuwe persberichten
    www.cytodyn.com/newsroom/press-releas...

    CytoDyn Submits its Top-line Report from its Phase 2 COVID-19 Trial to the U.S. FDA and Requests Emergency Use Approval

    Download as PDFAugust 17, 2020 6:00am EDT
    The Top-line Report has been sent to the regulatory authorities in Mexico, and will be provided to U.K. MHRA, and E.U. EMA, with requests for emergency use approval

    CytoDyn is preparing a Phase 3 protocol for leronlimab use in long-hauler COVID-19 individuals

    VANCOUVER, Washington, Aug. 17, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company announced today it has provided its Top-line Report from its recently completed, randomized, double-blind, Phase 2 trial for COVID-19 patients with mild-to-moderate symptoms to the U.S. Food and Drug Administration (FDA), and requested emergency use approval.

    In addition, CytoDyn has sent its Top-line Report of the Phase 2, mild-to-moderate COVID-19 population, to the regulatory authorities in Mexico and hopes to obtain emergency use approval from the MHRA in the U.K., EMA in the European Union, as well as the regulatory authorities in the Philippines.

    Along with the above activities, CytoDyn has been approached by several doctors about a clinical study of leronlimab in long-hauler COVID-19 individuals. The Company is preparing a Phase 3 protocol and will file it as soon as possible.

    www.cytodyn.com/newsroom/press-releas...

    CytoDyn Will Attempt to Duplicate Berlin and London Patients’ HIV Cure by Using Leronlimab During Bone Marrow Transplant for 5 HIV Patients Who also have Cancer

    Download as PDFAugust 17, 2020 6:15am EDT
    HIV monotherapy trials update: 215 patients completed almost one year of monotherapy. Only some were allowed to continue in extension arm; five patients reached almost 6 years. Twenty-five reached 2 to 4 years and 20 patients are 1 to 2 years

    VANCOUVER, Washington, Aug. 17, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company gives full update on all of its HIV programs.

    HIV Cure
    The HIV co-receptor CCR5 has proven to be a key molecule in mediating HIV remission. The only two individuals functionally cured of HIV, one from London and the other from Berlin, received allogeneic stem cell transplantations from CCR5-deficient donors. However, because it is extremely rare to find a stem cell donor who lacks CCR5 and meets stringent MHC matching criteria, such an approach is unfeasible to cure HIV on a larger scale. CytoDyn believes its CCR5 blocking antibody, leronlimab, could be used in the setting of allogeneic stem cell transplantation to functionally convert a stem cell graft from a wildtype CCR5 stem cell donor into one from a CCR5 deficient donor, and thereby functionally cure the recipient of HIV.

    CytoDyn plans to test this theory in a pilot clinical trial of five HIV patients with cancer who require bone marrow transplantation. Leronlimab will be used during the peri-transplant period to mimic a CCR5 deficient donor in order to achieve HIV cure.

    En net nu lanceert die Feuerstein een nieuwe aanval n.a.v. de laatste jaarcijfers. In Duitsland ging koers na opening dik onderuit. Na publicatie persberichten herstelde koers goed.
  8. forum rang 5 MisterBlues 17 augustus 2020 17:04
    quote:

    Dappie schreef op 17 augustus 2020 14:26:

    En net nu lanceert die Feuerstein een nieuwe aanval n.a.v. de laatste jaarcijfers. In Duitsland ging koers na opening dik onderuit. Na publicatie persberichten herstelde koers goed.
    Logisch dat het geshort en de short-geruchten nu weer kwamen. De beleggers met een GAK van boven de vier begonnen al te twijfelen. Dat geldt nu ook voor de range 3 tot 4. We zakken even goed weer richting een lage 3. PB's zijn in er de ogen van deze beleggers wat te vaak geweest...
  9. forum rang 4 nb 17 augustus 2020 18:02
    alles verkocht,( maar ik heb nie zoveul). toch nog iets van 150%, niet verkeerd
  10. forum rang 5 MisterBlues 17 augustus 2020 18:17
    quote:

    nb schreef op 17 augustus 2020 18:02:

    alles verkocht,( maar ik heb nie zoveul). toch nog iets van 150%, niet verkeerd
    Was je het zat? Geen vertrouwen meer?

    Tja, dat laatste persbericht lijk inderdaad eerder op een soort wanhoopspoging.
    Gelukkig had ik al 2x gehalveerd en blijf nu nog even zitten totdat we weer belachelijk laag staan. Ze zakken ook nog wel onder de 3.
  11. Dappie 17 augustus 2020 18:40
    FDA keurde in weekend nieuwe eenvoudige goedkope snelle test COVID goed. Door Yale universiteit ontwikkeld. Men kan daarmee sneller op de bal spelen. Minder goed nieuws wellicht voor sommige beurskoersen die op COVID ontwikkelen. Koers is al genoeg gezakt wat mij betreft. Hopen op Nasdaq uplisting en prima S/C resultaten.
  12. forum rang 5 MisterBlues 17 augustus 2020 18:46
    quote:

    Dappie schreef op 17 augustus 2020 18:40:

    FDA keurde in weekend nieuwe eenvoudige goedkope snelle test COVID goed. Door Yale universiteit ontwikkeld. Men kan daarmee sneller op de bal spelen. Minder goed nieuws wellicht voor sommige beurskoersen die op COVID ontwikkelen. Koers is al genoeg gezakt wat mij betreft. Hopen op Nasdaq uplisting en prima S/C resultaten.
    Zeker er zijn meer kapers op de kust, en het is beleggers duidelijk dat Cydy kostbare tijd kwijt raakt met een fase 3 M2M.

    Die Nasdaq uplisting kan je voorlopig vergeten, maar die S2C resultaten geloof ik ook nog in. Helaas zullen heel veel beleggers daar anders over denken.

    Ik hoop dat jij gelijk krijgt.
  13. [verwijderd] 17 augustus 2020 20:13
    Ik ben er ook uit, mooi ritje gemaakt, alhoewel het nog veel beter kon.
    Ben bang dat het een wirecardje, maar wens iedereen die erin blijft veel succes.
  14. forum rang 4 nb 17 augustus 2020 21:48
    quote:

    MisterBlues schreef op 17 augustus 2020 18:17:

    [...]

    Was je het zat? Geen vertrouwen meer?

    Tja, dat laatste persbericht lijk inderdaad eerder op een soort wanhoopspoging.
    Gelukkig had ik al 2x gehalveerd en blijf nu nog even zitten totdat we weer belachelijk laag staan. Ze zakken ook nog wel onder de 3.
    Ja, maar zat zijn is misschien te groot woord. Dit soort aandelen gaan zo vaak enorm op en neer. Ik hou het in de gaten en hoop later weer een kans te krijgen op lager niveau. Zo niet, heeft de blijver geluk.
    Kijk naar arwh, proqr, etc, allemaal potentie. Maar ook diepe dalen. Ik wil nog eerder stomweg afromen. Dan maar geen Porsche, fietsen is toch gezonder. :)
    Overigens, let op, het lijkt of arwh weer gaat vertrekken. JNJ--ARWH deal....?
  15. forum rang 5 MisterBlues 18 augustus 2020 00:24
    quote:

    nb schreef op 17 augustus 2020 21:48:

    [...]
    Ja, maar zat zijn is misschien te groot woord. Dit soort aandelen gaan zo vaak enorm op en neer. Ik hou het in de gaten en hoop later weer een kans te krijgen op lager niveau. Zo niet, heeft de blijver geluk.
    Kijk naar arwh, proqr, etc, allemaal potentie. Maar ook diepe dalen. Ik wil nog eerder stomweg afromen. Dan maar geen Porsche, fietsen is toch gezonder. :)
    Overigens, let op, het lijkt of arwh weer gaat vertrekken. JNJ--ARWH deal....?
    Je hebt gelijk: er komt een diep dal aan, want:

    Fase 3 M2M Geen van de andere autoriteiten zullen versneld goedkeuren op basis van Fase 2.

    Bij Fase 3 S2C zal een tussentijdse evaluatie (interim) waarschijnlijk zijn zodra de 195ste persoon de 28 dagen durende studie heeft voltooid. Tot nu toe zijn er 172 (volgens de CEO) ingeschreven. Dat duurt te lang.

    De concurrentie Relief, Synairgen, Regeneron, Gilead etc is nu zeker of vermoedelijk verder - al mag de kwaliteit in sommige gevallen minder zijn.

    Op basis van de koersgroei vanaf heel laag en het uitstel van het goede nieuws mag je verwachten dat er door shorters en winstnemers dagelijks 5-10% van de koers gaat. Einde van de week staat ie al 2,5$

    Eind augustus staat ie weer op 1$. Die koopmomentjes komen weer. En het Nader/Cydy circus gaat gewoon door. :) Ben wel blij dat ik me niet heb laten verrassen en stevig had afgebouwd en niet geluisterd heb naar de vroege instappers op dit forum.
1.071 Posts
Pagina: «« 1 ... 34 35 36 37 38 ... 54 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.286
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.467
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.960
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.500
Aedifica 2 832
Aegon 3.257 320.099
AFC Ajax 537 7.018
Affimed NV 2 5.762
ageas 5.843 109.779
Agfa-Gevaert 13 1.862
Ahold 3.536 73.983
Air France - KLM 1.024 34.350
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.774
Alfen 12 16.556
Allfunds Group 3 1.217
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 338
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.767
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.821 240.371
AMG 965 125.879
AMS 3 73
Amsterdam Commodities 303 6.523
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.164
Apollo Alternative Assets 1 17
Apple 5 319
Arcadis 251 8.623
Arcelor Mittal 2.024 318.674
Archos 1 1
Arcona Property Fund 1 267
arGEN-X 15 9.113
Aroundtown SA 1 176
Arrowhead Research 5 9.283
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.706
ASML 1.762 77.072
ASR Nederland 18 4.124
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.679
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 06 mei

    1. China inkoopmanagersindex diensten april
    2. PostNL Q1-cijfers
    3. Siemens Healthineers Q1-cijfers
    4. TKH Q1-cijfers
    5. Dui inkoopmanagersindex diensten april (def)
    6. EU inkoopmanagersindex diensten april (def) 52,9
    7. VK inkoopmanagersindex diensten april (def)
    8. EU producentenprijzen maart
    9. Tyson Foods Q1-cijfers
  2. 07 mei

    1. Japan inkoopmanagersindex diensten april
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht